Colchicine and arthropathy of behcet's disease
✍ Scribed by Venceslao Fossaluzza
- Publisher
- John Wiley and Sons
- Year
- 1982
- Tongue
- English
- Weight
- 106 KB
- Volume
- 25
- Category
- Article
- ISSN
- 0004-3591
No coin nor oath required. For personal study only.
✦ Synopsis
had gone into spontaneous clinical remission 5 years ago, but she also had the group's highest ESR (30 mm/hour). Control of her disease by suppressor T cells might be suggested, but her cells did not seem to bear the Ia marker (the percentage of OK1 1 + cells was not elevated), although the increase of expression of Ia antigens has been shown to be on the OKT 8+ subset (4).
These data indicate the importance of complete clinical, biologic, and therapeutic information to accurately define the clinical status of RA patients. We believe that a thorough study of patients in clinical remission would further the understanding of the biologic dysfunction that occurs in RA. Moreover, the use of other biologic parameters may help to define more precisely future subgroups of RA patients in clinical remission.
📜 SIMILAR VOLUMES
## LETTERS fluid C3 complement was 28 mg/dl with a serum C3 complement of 80 mg/dl. Examination of the synovial fluid under polarized light microscopy revealed multiple intracellular birefringent crystals. The crystals were small and the long axis could not be well determined, but they had the mor
Objective. Colchicine is a widely used treatment for Behc ¸et's syndrome, even though in a previous 6-month controlled study, it was shown to be effective only in controlling erythema nodosum and arthralgias. We reassessed the effect of colchicine in Behc ¸et's syndrome in a study conducted among a